Featured Speakers

• 

  Scot EbbinghausDirector Merck

• 

  Karthik VenkatakrishnanDirector Millennium

• 

  Jeffrey SchlomChief, Laboratory of Tumor Immunology & Biology NCI

• 

  Mark StumpGroup Leader Novartis

The FDA’s new stance on oncology drug combinations has unlocked a huge opportunity for cancer drug developers.

Finding out who has tried what and what is working is key if you want to fully capitalize on this change.

Combination Approaches to Cancer Therapy took place at the end of February 2012, and sought to solve these issues and accelerate progress in the development of combinatorial approaches.

Purchase Audio CD Presentations Online Now.

What was covered on the agenda?

• How to cut your development time by discovering new approaches for using dual novel combinations in oncology
• Obtaining speedy approval for your oncology drug through appreciation of the regulatory considerations
• Share the drug development burden by learning about the mutual benefits of industry/academic collaborations and how they can be performed in practise
• Boosting drug efficacy and enhance specific immunity: how you can use cancer vaccines in your combination
• Protecting your drug while trialling combinations by getting inside perspectives on the complex legal and IP implications of combination therapy 
• Mastering best practice in combination clinical trial design by hearing industry case studies first hand

Designed by industry leaders at Pfizer, AstraZeneca, Merck & Novartis this meeting brought together pharma heads of oncology drug development, business development & regulatory affairs with the leading clinicians and biotech executives. 

Who spoke:

• Jeffrey Schlom, Chief, Laboratory of Tumor Immunology and Biology, NCI
• Mark Stump, Group Leader, Novartis
• Jamey Skillings, VP, Medical Affairs, Pfizer 
• Chris Nicodemus, CSO, Advanced Immune Therapeutics
• Gangadhar Sunkara, Director Translational Sciences, Novartis 
• Jason Christofaro, Intellectual Property Advisor, NCI 
• Lydia McNally, Corporate IP Attorney, Novartis 
• Ton Logtenberg, CEO, Merus 
• Uday Khire, CEO, Allostem Therapeutics
• Lawrence Mayer, President & Head of Research, Celator Pharmaceuticals 
• Scot Ebbinghaus, Director, Merck 
• Peter Gilmore, Senior Partner, Oliver Wyman 
• John Maki, President and CEO, Vicus Therapeutics 
• Karthik Venkatakrishnan, Director, Clinical Pharmacology, Millennium

Who Attended?

• Head of oncology/cancer drug development from pharma
• C-level executives from biotech
• Heads of oncology regulatory/clinical affairs
• Heads of oncology business development/partnering
• CROs
• Lawyers and patent specialists